Ascendis Pharma A/S (ASND)

Ascendis Pharma Cash Flow Statement

Financials in millions EUR. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Net Income	-481.45	-583.19	-383.58	-418.96	-218.02
Depreciation & Amortization	18.91	17.96	15.39	9.45	6.69
Share-Based Compensation	66.66	64.18	66.83	53.17	37.49
Other Operating Activities	-71.49	5.36	-116.29	84.79	-2.1
Operating Cash Flow	-467.36	-495.7	-417.65	-271.55	-175.94
Capital Expenditures	-2.39	-4.95	-24.23	-16.5	-5.16
Acquisitions	0	0	-10.19	0	0
Change in Investments	288.87	66.69	-76.16	-274.7	0
Investing Cash Flow	286.47	61.73	-110.58	-291.2	-5.16
Share Issuance / Repurchase	10.29	-100.15	357.82	607.42	497.63
Debt Issued / Paid	125.82	496.93	-6.43	-4.77	-4.04
Other Financing Activities	-1.81	-	-	-	-
Financing Cash Flow	134.29	396.77	351.39	602.65	493.59
Exchange Rate Effect	-6.01	35.69	38.59	-53.49	7.75
Net Cash Flow	-46.6	-37.19	-176.84	39.9	312.5
Free Cash Flow	-469.75	-500.65	-441.88	-288.05	-181.1
Free Cash Flow Margin	-176.12%	-978.33%	-5681.19%	-4142.76%	-1353.98%
Free Cash Flow Per Share	-8.35	-8.93	-8.07	-5.69	-3.89

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).